Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

被引：0
|
作者：
Sharareh Seifi
Babak Salimi
Zahra Esfahani Monfared
Cyrus Sabahi
Hamidreza Kafi
Adnan Khosravi
机构：
[1] National Research Institute of Tuberculosis and Lung Diseases (NRITLD),Chronic Respiratory Disease Research Center
[2] Shahid Beheshti University of Medical Sciences,Faculty of Pharmacy
[3] Tehran University of Medical Sciences,Medical Department
[4] Orchid Pharmed Company,undefined
[5] Masih Daneshvari Hospital,undefined
来源：
Journal of Pharmaceutical Policy and Practice | / 16卷
关键词：
Non-small cell lung cancer; Observational study; Pemetrexed; Post-marketing surveillance; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
    Seifi, Sharareh
    Salimi, Babak
    Monfared, Zahra Esfahani
    Sabahi, Cyrus
    Kafi, Hamidreza
    Khosravi, Adnan
    [J]. JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2023, 16 (01)
  • [2] SAFETY AND EFFECTIVENESS OF PEMETREXED IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN JAPAN BASED ON POST-MARKETING SURVEILLANCE
    Okubo, Sumiko
    Kobayashi, Noriko
    Taketsuna, Masanori
    Enatsu, Sotaro
    Nishiuma, Shinichi
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S485 - S485
  • [3] Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer)
    Tomii, Keisuke
    Kato, Terufumi
    Takahashi, Masashi
    Noma, Satoshi
    Kobashi, Yoichiro
    Enatsu, Sotaro
    Okubo, Sumiko
    Kobayashi, Noriko
    Kudoh, Shoji
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (04) : 350 - 356
  • [4] Pemetrexed in the treatment of non-small-cell lung cancer and malignant pleural mesothelioma
    Kowalski, Dariusz M.
    Krawczyk, Pawel
    Jaskiewicz, Piotr
    Badurak, Pawel
    Krzakowski, Maciej
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 (06): : 292 - 300
  • [5] Pemetrexed prolongs survival in patients with malignant pleural mesothelioma or non-small-cell lung cancer
    不详
    [J]. Drugs & Therapy Perspectives, 2005, 21 (10) : 1 - 4
  • [6] Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
    Fujimoto, Nobukazu
    Akamatsu, Ayumi
    Honda, Chikara
    Aoki, Miki
    Ohe, Yuichiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [7] Pemetrexed (Alimta): Advancing the treatment of malignant pleural mesothelioma, non-small cell lung, pancreas, and other cancers - Introduction
    Bunn, PA
    Smith, IE
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (06) : 1 - 2
  • [8] Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: A post-marketing surveillance
    Yamamoto, Nobuyuki
    Kamitani, Tetsu
    Kanda, Kingo
    Ito, Yuichiro
    Hamada, Masahiro
    Ozaki, Masahiko
    Takeuchi, Noriko
    Yamada, Tomoko
    Kawano, Masaki
    Maekawa, Shinichiroh
    Kato, Terufumi
    [J]. CANCER SCIENCE, 2022, 113 (09) : 3110 - 3119
  • [9] Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines
    Naga, Shinjiro
    Takenaka, Kazumasa
    Sonobe, Makoto
    Wada, Hiromi
    Tanaka, Fumihiro
    [J]. CHEMOTHERAPY, 2008, 54 (03): : 166 - 175
  • [10] Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non-Small Cell Lung Cancer
    Dickgreber, Nicolas J.
    Fink, Thomas H.
    Latz, Jane E.
    Hossain, Anwar M.
    Musib, Luna C.
    Thomas, Michael
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (01) : 382 - 389
12345